Pancreatic Cancer 2022: Novel Targets from Sugar to Serotonin
Factors such as a dense tumor microenvironment, a lack of precise symptoms, and hard-to-target genetic mutations make pancreatic cancer...
Factors such as a dense tumor microenvironment, a lack of precise symptoms, and hard-to-target genetic mutations make pancreatic cancer...
At the end of last week, the U.S. Food and Drug Administration (FDA) approved the immunotherapeutic obinutuzumab (Gazyva) for...
Cancer Today and the AACR are hosting a webinar on Feb. 16 at 1 p.m. EST. A panel of...
June 2022 marked the 10th Annual Cancer Immunotherapy Month spearheaded by the Cancer Research Institute. Immunotherapy is an umbrella...
This year, at the AACR Annual Meeting held in Philadelphia April 18 to 22, an astounding 19,300 members of...
Researchers at Weill Cornell Medical College have identified a mutation that may be responsible in mantle cell lymphoma for...
Earlier this week, the U.S. Food and Drug Association (FDA) announced it had approved the immunotherapeutic atezolizumab (Tecentriq) for...
Guest Post by Barbara A. Conley, MD National Cancer Institute (NCI)
In the 1970s television series The Six Million Dollar Man, the narrator says of severely injured astronaut Steve Austin:...
Last week, the U.S. Food and Drug Administration (FDA) announced the first-ever approval of a treatment for Waldenström macroglobulinemia,...
Clinical trials are a crucial part of the cancer research continuum, providing a testing ground for the safety and...
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
On Monday, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of the immunotherapeutic...
Every person who hears the words “you have cancer” has a unique story. As part of Cancer Today’s mission...
As infections from SARS-CoV-2 began to rapidly spread across the United States in early 2020, many nonessential medical procedures, including cancer screenings, were...
About 80 percent of breast cancers express the estrogen receptor (ER). In ER-positive tumors, estrogen is the main driver...
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts...
The COVID-19 pandemic remains at the center of health and science news as cases of the disease continue to rise...
The cutting-edge scientific program for the AACR Virtual Annual Meeting I began Monday, April 27, with an Opening Clinical Plenary featuring...
The 2015 approval of an immune checkpoint inhibitor for renal cell carcinoma (RCC) provided a much-needed new treatment option...
Guest Post by Alan D. D’Andrea, MD, and Elizabeth M. Swisher, MD SU2C-OCRF-OCNA-NOCC Dream Team
The rapid fire of U.S. Food and Drug Administration (FDA) approvals of new anticancer therapeutics continued last week when...
In 2020, the COVID-19 pandemic was dominating the headlines, but CNN reporter Andrew Kaczynski was happy at home. He...
The U.S. Food and Drug Administration (FDA) has approved expanding the use of the immunotherapeutic pembrolizumab (Keytruda) to include...
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today The nationwide shutdown of elective clinical procedures implemented in...
Last year saw significant progress against lung cancer, with seven new therapeutics, including two immunotherapeutics, approved by the U.S....
Lung cancer awareness month started hot on the heels of two exciting pieces of news that highlight the promise...
This year, the American Association for Cancer Research (AACR) will celebrate its 115th birthday. From the very beginning, women...
Late last week, the U.S. Food and Drug Administration (FDA) added another antiangiogenic therapeutic to the armamentarium for oncologists...
The end of the year presents a unique opportunity to look back on recent accomplishments, take inventory of successes...